Structure Therapeutics (NASDAQ:GPCR) Trading Down 7.6% – What’s Next?

Structure Therapeutics Inc. (NASDAQ:GPCR) shares traded down 7.6% during mid-day trading on Monday . The company traded as low as $18.14 and last traded at $18.28. 27,802 shares were traded during trading, a decline of 97% from the average session volume of 840,175 shares. The stock had previously closed at $19.77.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. William Blair began coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They issued an “outperform” rating on the stock. Stifel Nicolaus assumed coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target for the company. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a report on Thursday, December 19th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Stock Down 8.8 %

The company’s 50 day simple moving average is $23.74 and its 200-day simple moving average is $30.82. The firm has a market cap of $905.45 million, a P/E ratio of -21.34 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. Equities research analysts predict that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Bank of Montreal Can increased its stake in shares of Structure Therapeutics by 71.6% during the third quarter. Bank of Montreal Can now owns 46,502 shares of the company’s stock valued at $1,941,000 after buying an additional 19,408 shares during the period. Verition Fund Management LLC lifted its holdings in Structure Therapeutics by 15.3% during the third quarter. Verition Fund Management LLC now owns 16,703 shares of the company’s stock worth $733,000 after buying an additional 2,218 shares during the period. Cinctive Capital Management LP boosted its position in Structure Therapeutics by 111.0% during the 3rd quarter. Cinctive Capital Management LP now owns 32,094 shares of the company’s stock valued at $1,409,000 after acquiring an additional 16,883 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Structure Therapeutics by 18.0% in the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after acquiring an additional 602,609 shares in the last quarter. Finally, Ikarian Capital LLC purchased a new stake in shares of Structure Therapeutics during the 3rd quarter worth $5,056,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.